OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine
OnabotulinumtoxinA is effective in approximately 1/3 patients with NDPH and has a favourable safety profile.
Authors
- Manjit Singh Matharu (ORCID: https://orcid.org/0000-0002-4960-2294)
- Salwa Kamourieh (ORCID: https://orcid.org/0009-0009-3718-3772)
- Susie Lagrata (ORCID: https://orcid.org/0000-0002-5672-5540)
- Khadija Rantell (ORCID: https://orcid.org/0000-0002-6747-7650)
- Sanjay Cheema (ORCID: https://orcid.org/0000-0002-5438-6549)
- Maha Ahmed
Institutions
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Cephalalgia
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1177/03331024251317448
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.88